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Staphylococcus aureus is a virulent pathogen that is responsible for a wide range of superficial and invasive infections. Its resis-
tance to existing antimicrobial drugs is a global problem, and the development of novel antimicrobial agents is crucial. Antimi-
crobial peptides from natural resources offer potential as new treatments against staphylococcal infections. In the current study,
we have examined the antimicrobial properties of peptides isolated from anuran skin secretions and cyclized synthetic analogues
of these peptides. The structures of the peptides were elucidated by nuclear magnetic resonance (NMR) spectroscopy, revealing
high structural and sequence similarity with each other and with sunflower trypsin inhibitor 1 (SFTI-1). SFTI-1 is an ultrastable
cyclic peptide isolated from sunflower seeds that has subnanomolar trypsin inhibitory activity, and this scaffold offers pharma-
ceutically relevant characteristics. The five anuran peptides were nonhemolytic and noncytotoxic and had trypsin inhibitory
activities similar to that of SFTI-1. They demonstrated weak in vitro inhibitory activities against S. aureus, but several had
strong antibacterial activities against S. aureus in an in vivo murine wound infection model. pYR, an immunomodulatory pep-
tide from Rana sevosa, was the most potent, with complete bacterial clearance at 3 mg · kg1. Cyclization of the peptides im-
proved their stability but was associated with a concomitant decrease in antimicrobial activity. In summary, these anuran pep-
tides are promising as novel therapeutic agents for treating infections from a clinically resistant pathogen.
Staphylococcus aureus is one of the most virulent and opportu-nistic pathogens, causing increasing numbers of nosocomial
and community-acquired infections, and is a leading cause of skin
and soft tissue infections (1–3). These Gram-positive cocci pro-
duce a myriad of virulence factors that allow the bacteria to attach
to host cells, to invade tissues, to evade the host immune system,
and to release an array of exoproteins and toxins (4, 5). Conta-
gious S. aureus skin infections can lead to severe muscle or bone
infections that ultimately can spread to the lungs or heart (6). The
primary treatment involves prescription of -lactam antibiotics
such as penicillins and cephalosporins, along with clinical wound-
cleaning procedures (6, 7). Strains resistant to antibiotics have
been emerging since the 1960s, however, especially methicillin-
resistant S. aureus (MRSA), which is most common in nosoco-
mial skin infections (8). Alarmingly, there have been reports of
S. aureus strains that are resistant to the drug of last resort,
vancomycin (9).
Antimicrobial peptides are now recognized as novel alternative
therapeutic agents for infection control (10). Several hypotheses
have been examined regarding the mode of action of antimicro-
bial peptides, including autolysin activation, lipopolysaccharide
(LPS) permeabilization, fatal depolarization of the energized bac-
terial membrane, formation of barrel-stave pores that cause leak-
age of cellular contents, activation of processes that degrade the
cell wall, membrane thinning/thickening, impairment of essential
intracellular targets after internalization, and disturbance of the
distribution of cellular membrane lipids (11–15). Attributes of
antimicrobial peptides that make them viable candidates for de-
velopment as anti-infective therapeutic agents include broad-
spectrum antimicrobial activity, novel mechanisms of action and
ease of manipulation, and synthesis and tailoring of peptide se-
quences (16, 17). Conversely, major obstacles to the successful
development of antimicrobial peptides as therapies include their
potential toxicity, high manufacturing costs, and degradation due
to proteases, heat, or extremes of pH (10). The design of peptides
that are stable against these processes while maintaining their an-
timicrobial properties would be a breakthrough in this field.
In amphibians, antimicrobial peptides play an important role
in defense against pathogenic microbes. The skin secretions of
anuran frogs contain a cocktail of compounds, with various bio-
logical activities, that have potential for drug development (18).
Among these secreted compounds are the anuran antimicrobial
peptides, which have a broad range of antibacterial and antifungal
activities (19). These ribosomally synthesized peptides of 8 to 63
amino acids have high affinity for microbial cell membranes (20).
They also have serine protease inhibitory activity (21–23).
The amphibian antimicrobial peptides shown in Table 1 con-
tain a conserved Bowman-Birk inhibitor (BBI)-like (24) trypsin
inhibitory loop (CWTKSIPPKPC) and share high sequence ho-
mology and structural similarities with sunflower trypsin inhibi-
tor 1 (SFTI-1), a 14-amino-acid cyclic peptide discovered in sun-
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flower seeds (Helianthus annuus) (25). SFTI-1 is the smallest and
one of the most potent BBIs. The structure of SFTI-1 has an ex-
tensive hydrogen bonding network and a disulfide bond connect-
ing two -strands, which form a tightly folded scaffold with two
distinct loops, namely, the trypsin binding loop (loop 1) and the
secondary loop (loop 2) (26). Loop 1 contains the active site resi-
due for trypsin inhibitory activity, and loop 2 contains the site for
backbone cyclization in the natural biosynthetic process. The an-
uran peptides studied have additional conserved residues in the
binding loop (W and P) and additional residues in the secondary
loop, where only the glycine preceding the first cysteine residue is
conserved. Based on these sequence similarities, we have termed
these anuran peptides with similarity to SFTI-1 the SFTI-1-like
frog (SLF) peptides.
The cyclic nature of SFTI-1 contributes to its stability and its
resistance to degradation by proteases (26), which is a limitation
of linear antimicrobial peptides. Cyclization has been used as one
of the strategies in drug design to improve stability; for example,
cyclization of the antimicrobial peptide pyrrhocoricin improved
its in vivopharmaceutical properties (27). The in vitro stability and
antimalarial activity of the antimicrobial peptide gomesin, from
the Brazilian spider Acanthoscurria gomesiana, were also im-
proved after backbone cyclization (28).
In this study, a series of SLF peptides were evaluated for their in
vivo efficacy in a murine Staphylococcus aureus wound infection
model. Three of the active peptides were cyclized in an attempt to
improve their stability. The structures of the most active peptide
and its cyclic analogue were determined to elucidate the effects of
cyclization on their antimicrobial and trypsin inhibitory activities.
MATERIALS AND METHODS
Peptide synthesis and purification. 9-Fluorenylmethoxycarbonyl
(Fmoc)-based chemistry was used to synthesize linear peptides on an
automated synthesizer (Symphony; Protein Technologies, Inc.). 2-Chlo-
rotrityl resin (Novabiochem) was used to assemble the peptide chain, and
amino acids were Fmoc deprotected using 30% piperidine (Auspep Pty.
Ltd.) in dimethylformamide (DMF). Fmoc-protected amino acids (CS
Bio Co.) were coupled with HCTU [O-(6-chlorobenzotriazol-1-yl)-
N,N,N=,N=-tetramethyluronium hexafluorophosphate] (Peptide Interna-
tional) and DIPEA (N,N-diisopropylethylamine) (Auspep Pty. Ltd.) in
DMF (RCI Labscan Ltd.) (28). The cyclic peptides were synthesized by
t-butyloxycarbonyl (Boc)-based solid-phase peptide synthesis using stan-
dard protocols (29, 30). A thioester-based linker (-mercaptopropionic
acid) was used to facilitate cyclization by native chemical ligation (NCL)
(31). Previously described standard protocols for hydrogen fluoride
cleavage were used to cleave the peptides from the resin (32). The cleaved
linear reduced peptides were purified by C18 reverse-phase (RP)-high-
performance liquid chromatography (HPLC) using a gradient of buffer B
(90% acetonitrile in 0.05% aqueous trifluoroacetic acid [TFA]) and buffer
A (0.05% aqueous TFA) of 1% per minute. Peptide cyclization was
achieved by native chemical ligation with a procedure involving two steps,
i.e., cyclization in the presence of a reducing agent (TCEP [tris(2-carboxy-
ethyl)phosphine]) followed by oxidation, with both steps involving over-
night stirring at room temperature in 0.1 M ammonium bicarbonate
buffer (pH 8.5). Peptides were purified by RP-HPLC at each step. The
molecular weight and purity of the peptides were confirmed by liq-
uid chromatography-electrospray ionization-mass spectrometry (LC-
ESI-MS).
Structure determination by NMR spectroscopy. 1H nuclear mag-
netic resonance (NMR) measurements were carried out with a Bruker
Avance-600 spectrometer for all peptides. Each peptide (3 mg) was
dissolved in 90% H2O-10% D2O (99.9 and 99.99%, respectively; Cam-
bridge Isotope Laboratories, Woburn, MA) at pH 5, and DSS (4,4-di-
methyl-4-silapentane-1-sulfonic acid) was added as a chemical shift ref-
erence. Two-dimensional NMR data were recorded in phase-sensitive
mode using time-proportional phase incrementation for quadrature de-
tection in the t1 dimension (33). Total correlation spectroscopy (TOCSY)
experiments used an MLEV-17 spin-lock sequence (34) with a mixing
time of 80 ms, and nuclear Overhauser effect spectroscopy (NOESY) ex-
periments used mixing times of 100 to 200 ms (35). Amide proton tem-
perature sensitivity and deuterium exchange experiments were conducted
to determine hydrogen-bonding constraints. Taloswas used for predic-
tion of the  and  backbone angles (36). Structural calculations were
carried out with CYANA 3.0, using torsion angle dynamics. The 20 low-
est-energy structures with the best MolProbity scores were selected for the
final ensemble (37).
Trypsin inhibition. Trypsin inhibition constants (Ki) of the peptides
were measured by a rapid microplate assay using a modification of the
method described by Erlanger et al. (38). Reactions were conducted in a
96-well plate containing 15 l of 0.45 mg/ml bovine pancreatic trypsin
(Sigma-Aldrich), 5l of buffer (50 mM Tris, 20 mM CaCl2 [pH 8.2]), 125
l of 0.435 mg/ml L-BAPNA (N-benzoyl-L-arginine-4-nitroanilide hy-
drochloride) (Sigma-Aldrich), and peptides at final concentrations rang-
ing from 6.67 mM to 0.065 mM. The reaction was quenched with 25l of
TABLE 1 Characteristics of SLF peptides from anuran skin secretions that were highly similar to SFTI-1
Peptide Origin Sequencea
Peptide property
NC aHI pI
Composition (%)
HY BA NE AC
ORB Odorrana grahami 5.9 	0.42 11.0 40 25 35 0
ORB2K Odorrana grahami 4.9 	0.44 10.6 35 24 41 0
pYR Rana sevosa 4.9 	0.87 10.9 39 22 39 0
Rana-Eb Rana esculenta 4.9 	1.22 10.5 29 24 47 0
Rana-Tb Rana temporaria 4.9 	0.88 10.5 35 25 41 0
SFTI-1 Helianthus annuus 0.9 	0.13 8.3 36 14 43 7
a Peptides contain a Bowman-Birk inhibitor (BBI) reactive loop (enclosed in dashed box) and a disulfide bond (black lines). SFTI-1 has a naturally cyclic backbone (gray line). NC,
net charge; aHI, grand average of hydropathicity index; pI, isoelectric point; HY, hydrophobic amino acids; BA, basic amino acids; NE, neutral amino acids; AC, acidic amino acids.
b Ranacyclin peptides are abbreviated as Rana.
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30% acetic acid after 10 min of incubation at 25°C. A PowerWave XS plate
reader (Bio-Tek) was used to measure the absorbance of p-nitroanilide
(pNA) at 410 nm.
In vitro antimicrobial assays. The MICs of peptides against S. aureus
were determined using the standardized serial dilution method, according
to North Carolina Science Leadership Association (NCSLA) guidelines
(39). Overnight colonies of Staphylococcus aureus (strain ATCC 29213)
were suspended and standardized at 0.5 units by a turbidity method, fol-
lowed by dilution in Mueller-Hinton (MH) broth. For MIC determina-
tions, peptides were added at 1 to 200 M concentrations from a stock
solution, and gentamicin was used as a positive control. Each well of the
96-well plate contained 90l of bacteria (1
 105 cells) in MH agar and 10
l of peptide solution. Ampicillin (40 mg · ml	1) and phosphate-buffered
saline (PBS) were used as positive and negative controls, respectively.
Each data point was measured in triplicate. The polypropylene plates were
incubated for 24 h at 37°C. Peptide MICs were determined as the lowest
tested concentration that resulted in 100% development inhibition, in
comparison to the negative control. The MIC is defined as the lowest
concentration of an antimicrobial compound that completely inhibits the
growth of the organism, as detected by the unaided eye (40).
Hemolytic assays. All peptides were tested for their abilities to hemo-
lyze red blood cells (RBCs). Using a previously described method (41),
serially diluted peptides (final concentrations of 0.4 to 50M) were incu-
bated with human RBCs in 96-well plates for 1 h at 37°C and then were
centrifuged at 150 relative centrifugal force (RCF) for 5 min. The absor-
bance of the supernatant, containing plasma and lysed RBCs, was mea-
sured at 415 nm with a PowerWave XS plate reader (Bio-Tek). Triton
X-100 (0.1%) and PBS were used as positive and negative controls, respec-
tively. Melittin, a cationic hemolytic peptide, was used as a positive con-
trol and was tested at initial concentrations ranging from 0.4 to 50 M.
Percent hemolysis was calculated using the absorbance of maximum lysis
in the positive-control samples (Triton X-100).
Cell cytotoxicity. The cytotoxic effects of anuran peptides on human
foreskin fibroblast (HFF-1) cells and melanoma (MM96L) cells were eval-
uated using an MTT [3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tet-
razolium bromide] assay. Cells were seeded in 96-well plates at 3 
 103
cells/well (100l) with 15% fetal bovine serum (FBS) in Dulbecco’s mod-
ified Eagle’s medium (DMEM) for HFF-1 cells (Gibco) or 10% FBS in
RPMI 1640 medium for MM96L cells, supplemented with 2 mM L-glu-
tamine and 1 mM sodium pyruvate (Gibco). All cells were incubated at
37°C in 5% CO2 for 24 h. The medium was removed and replaced with
fresh serum-free medium (90 l/well), and then peptides were added. All
peptides were tested in triplicate, with final peptide concentrations rang-
ing from 1 to 200 M, and were incubated with cells for 2 h. A negative
vehicle control (water) and a positive control (1% Triton X-100) were
included in the assay. After 2 h of incubation, 10 l of MTT (5 mg/ml in
PBS) was added to each well, and the cells were further incubated for 3 h
before the removal of supernatant. The formazan crystals formed in each
well were dissolved in 100l dimethylsulfoxide (DMSO), and absorbance
was measured at 600 nm using a BioTek PowerWave XS spectrophotom-
eter. Data were analyzed using the GraphPad Prism program, and 50%
inhibitory concentration (IC50) values were obtained from the sigmoidal
dose-response curves.
Acute toxicity. Acute toxicity assays were based on the method de-
scribed by Navon-Venezia and coworkers (42), with intraperitoneal (i.p.)
administration of the tested peptides to groups of 10 C57BL/6 mice. Each
mouse was injected with 0.5 ml of a solution of freshly prepared pyR or
cpYR in PBS. The doses of peptides administered per mouse were 0, 5, 10,
25, 50, and 100 mg · kg of body weight	1. Animals were inspected for
adverse effects for 30 min, and survival was monitored for 6 h thereafter.
In vivo antimicrobial activity. Female C57BL6 mice (6 to 8 weeks of
age) were obtained from CEMIB-Unicamp (Brazil). The study was ap-
proved by the Animal Use Committee at the Institute of Biological Sci-
ences, University of Brasilia. Briefly, groups of mice (n 4/group in each
experiment) were anesthetized with a combination of ketamine and xyla-
zine, their backs were shaved, and the surgical area was disinfected with
70% ethanol. A 1-cm incision was made, and 25 l with 2
 109 CFU S.
aureus was pipetted into the incision. The mice were euthanized at 7 days
after surgery, and the wound tissue was excised, weighed, and homoge-
nized in 1 ml of PBS. Serial dilutions of the homogenates were plated in
triplicate on mannitol salt agar plates, and results were expressed as CFU/
gram of tissue. Peptides were administered to animals daily. Peptides were
solubilized in water for injection at two different concentrations, 1.5 mg ·
kg	1 and 3.0 mg · kg	1, and were injected into the wound in a 25-l
volume; PBS was used as a negative control and 10 mg · kg	1 neomycin
sulfate as a positive control.
Serum stability. The linear and cyclic forms of pYR and SFTI-1 pep-
tides were evaluated in serum stability assays using an established method
(30). Human AB serum (Sigma) was used in this assay. Lipids were re-
moved by centrifugation at 13,000 rpm for 15 min prior to the assay.
Peptides (initial concentration, 2 mg/ml) diluted 10-fold in serum (test)
or PBS (negative control) were incubated at 37°C. At each time point (0, 3,
6, 10, and 24 h), triplicate aliquots were taken from each peptide sample in
serum or PBS and denatured with equal volumes of 6 M urea, followed by
10 min of incubation at 4°C. The serum proteins were then precipitated
with an equal volume of 20% trichloroacetic acid, with a 10-min incuba-
tion at 4°C followed by centrifugation at 13,000 rpm for 15 min. The
supernatant was stored at 4°C until analysis. The relative concentration of
the intact peptide, in comparison with the level at the start of the experi-
ment, was measured by ultra-high performance liquid chromatography
(uHPLC) for each peptide sample, using the integrated area of the peak
corresponding to the intact peptide (with UV absorbance at 214 nm) on
the HPLC trace. The mean and standard deviation were calculated for
each peptide.
RESULTS
Synthesis of antimicrobial peptides. The SLF peptides (Table 1)
were synthesized to study their structures, biological characteris-
tics, and in vivo antimicrobial efficacy against S. aureus in an ani-
mal wound infection model. The cyclic versions of the SLF pep-
tides are prefixed with c, and the open or acyclic form of SFTI-1 is
prefixed with o. The native open-chain peptides were synthesized
using Fmoc-based chemistry and were oxidized in ammonium
bicarbonate buffer (pH 8.5). SFTI and the cyclic versions of the
anuran peptides were synthesized using Boc-based chemistry with
a C-terminal thioester to facilitate cyclization. Cyclization (in the
presence of reducing agent) and oxidation were carried out in two
separate steps. These conditions led to efficient cyclization of pep-
tides without the requirement for additional linker residues.
Structure determinationbyNMRspectroscopy.The peptides
were analyzed by NMR spectroscopy. The secondary H chemical
shifts (Fig. 1) were calculated using the measured chemical shifts
and the random coil values reported by Wishart et al. (43). Sec-
ondary H chemical shifts are highly sensitive to structural mod-
ifications, and thus they offer an excellent platform to observe
structural differences due to amino acid variations (44). The linear
and cyclic constructs had comparable chemical shifts, suggesting
that the cyclization of the backbone did not have a significant
influence on structure. The first proline in the binding loop (CX
TKSIPPK/IP) is in a cis conformation, consistent with SFTI-1
(32). The other proline residues are in a trans conformation in all
peptides.
The three-dimensional structures of open and cyclic pYR (Fig.
2) were elucidated using the program CYANA, and the ensembles
chosen to represent the final structures were based on the 20 struc-
tures from a set of 100 structures with the lowest MolProbity
scores (37, 45). Statistics showing the precision and stereochemi-
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cal qualities of the pYR structures are presented in Table 2. In the
cyclic form, the loop with the disulfide bond (loop 2) showed less
structural variation than the loop with the free termini (loop 1).
In vitro biological activity. The SLF peptides contain a BBI
loop similar to SFTI-1. For this reason, the trypsin inhibitory ac-
tivities of the SLF peptides were assessed and compared with that
of SFTI-1 (Fig. 3), which has been reported to have an inhibition
constant of 1.7 pM (29). cpYR was found to have trypsin inhibi-
tory activity similar to that of SFTI-1. The other peptides had
significantly reduced inhibitory activity, ranging between 13 and
50%, relative to SFTI-1. Cyclization improved the inhibitory ac-
tivities of all peptides, but opening of the SFTI-1 chain resulted in
decreased inhibitory activity, compared to wild-type SFTI-1, con-
sistent with previous studies (26).
The antimicrobial activities of the peptides were measured in
an in vitro assay with the widely used sensitive S. aureus strain
ATCC 29213, on MH agar, using a dilution method. Table 3 pres-
ents the MIC data for open and cyclic forms of the peptides. pYR
was the most potent peptide, with an MIC of 50 M against S.
aureus. Rana-E and Rana-T showed MICs of 100M, whereas the
other open peptides had MICs greater than 100 M. Backbone
cyclization resulted in decreased potency of pYR, while MIC val-
ues for cORB and cORB2K were 100 M. Cyclic and open
SFTI-1 forms had no antimicrobial activity at concentrations up
to 100 M.
The hemolytic activities of all peptides were determined in hu-
man blood. Melittin, a well-studied and highly hemolytic peptide
from honeybee venom (46), and Triton X-100 were used as a
positive controls and PBS was used as a negative control in the
assay. All peptides were found to be nonhemolytic at up to 50M
concentrations (data not shown). To further evaluate the toxicity
and effects of cyclization of these peptides, the cytotoxicities of
open and cyclic pYR and ORB were determined with human fore-
skin fibroblast (HFF-1) and melanoma (MM96L) cell lines. The
peptides were noncytotoxic at up to 200 M, except for cpYR,
which was found to kill 20% of the cells in both cell lines at 200M
(Fig. 4).
Acute toxicity. Toxicity was assessed in vivo for pYR and cpYR.
FIG 1 HNMR secondary shift analysis of SLF peptides and SFTI-1. Second-
ary shifts were obtained by subtracting experimental 1H NMR H chemical
shifts from random coil shifts for the corresponding residue (43). The ORB/
ORB2k open and cyclic peptides have similar shifts in loop 1, whereas the
Rana-E/T and pYR peptides have similar secondary shifts in loop 1. Loop 1
contains a highly conserved BBI reactive loop (dotted gray box).
FIG 2 NMR solution structures of open and cyclic pYR. (A and B) Structural
ensembles of open (A) and cyclic (B) pYR. Disulfide bonds are highlighted in
gray. (C) Three-dimensional structural comparison of pYR peptides with
truncated ORB2K (PDB accession number 2O9Q) and SFTI-1 (PDB accession
number 1JBL).
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First, acute toxicity was examined after i.p. administration of a
single dose of each peptide to groups of C57BL/6 mice (n  5
mice/group). No immediate adverse events were noted for the
peptides at doses of up to 25 mg · kg	1 (Table 4). Toxicity level I,
involving narrowing of the eyes, was noted minutes after injection
in mice injected with doses of peptides above 50 mg · kg	1, except
for one animal with pYR at 50 mg · kg	1. Toxicity level II, involv-
ing crouching and cuddling, was observed in a few mice injected
with doses of pYR or neomycin sulfate above 50 mg · kg	1. No
deaths were observed for any of the treated mice, and most mice
recovered 2 h after treatment.
In vivo antimicrobial activity. The therapeutic efficacy of the
anuran defense peptides against S. aureus was studied in a murine
wound infection model (Fig. 5). The wound was infected with 2

109 CFU of S. aureus ATCC 29213 at the start of therapy, and
changes in bacterial loads were evaluated after 7 days of daily an-
timicrobial therapy with antimicrobial peptides. The negative-
control group of mice (untreated group) was given PBS instead of
antimicrobial agent, whereas the positive-control group was
treated with neomycin sulfate antibiotic at 10 mg · kg	1 (antibi-
otic-treated group). Neomycin sulfate is an antibiotic from the
aminogylcoside family that is used in topical ointments, and this
has been used to study S. aureus infections (47, 48). The bacterial
recoveries for the antibiotic-treated group and the untreated
group were found to be 4.1  1.0 and 10.9  0.3 log10CFU/g of
tissue, respectively.
The antimicrobial peptides were administered daily at the site
of infection at doses of 1 or 3 mg · kg	1. The bacterial recovery for
TABLE 2 Structural statistics for NMR solution structures of pYR and cpYR
Parameter pYR cpYR
Experimental restraintsa
No. of interproton distance restraints 170 202
No. of intraresidue restraints 39 51
No. of sequential restraints 72 80
No. of medium-range (i	 j of5) restraints 27 27
No. of long-range (i	 j of5) restraints 32 44
No. of hydrogen bond restraintsb 4 4
No. of disulfide bond restraints 2 2
No. of dihedral angle restraints ( and) 20 22
RMS deviation from mean (mean SD)c
Backbone atoms (residues 22-45) 1.27 0.53 0.72 0.33
Heavy atoms (residues 22-45) 2.53 0.83 2.13 0.65
Stereochemical quality (mean SD)d
Residues in most favored Ramachandran region (%) 96.47 4.83 87.50 2.99
Ramachandran outliers (%) 0.29 1.31 0.31 1.40
Unfavorable side chain rotamers (%) 8.82 7.27 11.00 8.72
Clash score, all atoms (no. of overlaps/1,000 atoms)e 13.55 2.30 8.97 3.16
Overall MolProbity score 2.41 0.50 2.74 0.34
a Only structurally relevant restraints, as defined by CYANA, are included.
b Two restraints were used per hydrogen bond.
c RMS, root mean square; SD, standard deviation.
d Stereochemical properties were obtained by MolProbity (http://molprobity.biochem.duke.edu).
e The clash score is defined as the number of steric overlaps of0.4 Å per 1,000 atoms.
FIG 3 Relative trypsin inhibitory activities of SLF peptides, compared with
SFTI-1. SFTI-1 has an equilibrium dissociation constantKi of 17 pM (29). The
statistical significance was calculated with respect to SFTI-1 by one-way anal-
ysis of variance (ANOVA) and the post hoc Bonferroni test. , P 0.0001.
TABLE 3 In vitro efficacy of SLF peptides against Staphylococcus aureus
strain ATCC 29213
Peptide MIC (M)
ORB 100
cORB 100
ORB2k 100
cORB2k 100
pYR 50
cpYR 75
Rana-E 100
Rana-T 100
oSFTI-1 100
SFTI-1 100
Gentamicin 48
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pYR at 3 mg · kg	1 was found to be 4.3 0.7 log10CFU/g of tissue,
which was equivalent to the antibiotic control (20 mg · kg	1).
Lowering the dose of pYR by one-third increased the bacterial
recovery 1.5-fold. The other open-form anuran peptides signif-
icantly reduced the numbers of log10CFU/g of tissue, compared
to the untreated group of mice; however, they were less efficient
than pYR.
Backbone cyclization of the peptides resulted in a decrease or
loss of antimicrobial activity. The cyclic analogue (cpYR) of the
most active open peptide (pYR) completely lost therapeutic effi-
cacy even at 3 mg · kg	1. cORB and cORB2K showed reduced
bacterial clearance in wounds by 1 to 1.5 log10 CFU/g of tissue,
compared to their respective open forms.
Serum stability. The open and cyclic forms of pYR and SFTI-1
were incubated in human serum (Fig. 6), and the cyclic peptides
were found to have improved stability over the open forms over 24
h. SFTI-1 did not degrade at all, whereas 57.2  0.9% of cpYR
degraded after 24 h. oSFTI-1 was more stable than pYR.
DISCUSSION
Antimicrobial peptides are found in both animal and plant species
and are used in host defense mechanisms. There is growing inter-
est in exploring the potential of antimicrobial peptides as antibi-
otics to combat the decreased efficacy of conventional small-mol-
ecule antibiotics (49, 50). Some antimicrobial peptides kill
microbes directly, while others are effective by modulating the
innate immune system (51). The ability of antimicrobial peptides
to neutralize endotoxemia/sepsis and to stimulate host innate re-
sponses while dampening potentially deleterious inflammatory
responses offers an added advantage over small-molecule antibi-
otics (17). In this study, five antimicrobial peptides of anuran
origin, containing a reactive site loop of BBIs, were evaluated for
their therapeutic efficacy to treat S. aureus-infected wounds in
mice. Three active peptides were backbone cyclized in an attempt
to improve their biological properties.
Several SLF peptides have been reported to have in vitro anti-
microbial activity against a range of microbes, but only ORB and
ORB2K have been tested against S. aureus ATCC 25923 (21–23).
In light of these observations, we evaluated the in vitro antimicro-
bial activities of five SLF peptides against S. aureus strain ATCC
29213, a strain isolated from wounds (Table 3). ORB and ORB2K
were found to have much greater inhibitory activities than re-
ported (21). Variations in the antimicrobial susceptibility testing
methods have been found to have significant effects on the MICs
of compounds, as demonstrated using the cysteine-rich antimi-
crobial peptide protegrin-1, for example (52). Differences are also
dependent on the characteristics of the antimicrobial agents, in-
cluding hydrophobic moments, exposed charges, amphipathicity,
and peptide flexibility (53, 54). pYR was found to be the most
active SLF peptide, while others had moderate-to-poor antimicro-
bial activity. Loop 2 of these SLF peptides has significant sequence
diversity, compared to loop 1, and this diversity in the length and
number of hydrophobic and cationic residues might be responsi-
ble for the observed variations in antimicrobial activity.
The high sequence similarity of the anuran peptides to SFTI-1,
a stable and naturally cyclic peptide, guided this study toward the
development of cyclic antimicrobial peptides that could poten-
tially have improved stability and biological activities. Therefore,
TABLE 4 Evaluation of acute toxicity in mice treated with pYR, cpYR,
or neomycin sulfate (positive control)
Dose (mg · kg	1) and
effecta
No. of mice (n 5/group)
Neomycin sulfate pYR cpYR
0
No effect 5 5 5
Toxicity level I 0 0 0
Toxicity level II 0 0 0
5
No effect 5 5 5
Toxicity level I 0 0 0
Toxicity level II 0 0 0
10
No effect 5 5 5
Toxicity level I 0 0 0
Toxicity level II 0 0 0
25
No effect 3 4 5
Toxicity level I 2 1 0
Toxicity level II 0 0 0
50
No effect 2 2 4
Toxicity level I 0 2 1
Toxicity level II 3 1 0
100
No effect 2 1 3
Toxicity level I 0 2 2
Toxicity level II 3 2 0
a Toxicity grading was as follows: level I, narrowing of eyes; level II, crouching and
cuddling.
FIG 4 Cytotoxic activity of selected ORB and pYR peptides against noncan-
cerous (HFF-1) (A) and cancerous (MM96L) (B) cells. Both open and cyclic
forms of the peptides were tested, and melittin was used as a positive control
(0% viability corresponds to 100% cell death).
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pYR, ORB, and ORB2K were cyclized using a method previously
used for SFTI-1 (29, 32). Cyclization of a peptide backbone has
been used previously to effectively improve in vitro stability, but
the proximity between the N and C termini has a significant influ-
ence on the ease of cyclization (55, 56). Apart from contributing to
structural stability, head-to-tail cyclization provides useful in-
sights into the significance of the C and N termini of peptides in
biological activity and folding (57). The structures of pYR, ORB,
and ORB2K were found to be well suited for cyclization, as the
overall folding was maintained following cyclization. Cyclization
of pYR decreased the in vitro antimicrobial activity but improved
the stability of the peptide in serum. The decrease in antimicrobial
activity might be related to the loss of flexibility in residues near
the termini and the positive charge at the N terminus. Since the
antimicrobial activities of ORB, ORB2K, and SFTI-1 were above
the upper limit of the in vitro assay, the impact of cyclization on
the stability of these peptides was not examined.
The specificity of the peptides for bacterial cells was examined
by analysis of their hemolytic activities and their cytotoxicities for
mammalian cells. None of the peptides was found to exhibit he-
molytic activity. Open and cyclic forms of pYR and ORB were not
cytotoxic to human foreskin fibroblast or melanoma cells. The
lack of hemolytic and cytotoxicity activity with human cells indi-
cated that the SLF peptides are selective for bacterial cells. pYR,
cpYR, and neomycin sulfate did not cause acute toxicity at clini-
cally used doses (10 mg · kg	1), while mild toxicity at doses of 25,
50, or 100 mg · kg	1 was seen in a few animals from each group.
Toxic effects were resolved after 2 h in most cases.
We evaluated the in vivo efficacy of the SLF peptides for the
treatment of S. aureus skin infections in the widely used C57BL
mouse model. The relationship between the in vitro efficacy and
the in vivo efficacy of antimicrobial agents remains unclear, and
FIG 5 In vivo efficacy of SLF peptides against S. aureus in the murine thigh infection model. Both open (A) and cyclic (B) forms were tested at 1 and 3 mg · kg	1
(5 animals tested per compound). PBS and neomycin sulfate (3 mg · kg	1) were used as negative (C	) and positive (C) controls, respectively. The statistical
significance was calculated with respect to the untreated group (C	) by one-way ANOVA and the post hoc Bonferroni test. , P 0.01; , P 0.001; ,
P 0.0001.
FIG 6 Serum stability of open and cyclic forms of pYR and SFTI-1. Backbone-
cyclized pYR and SFTI-1 had better stability in human serum than did their
open forms.
Peptides for Treating Staphylococcal Skin Infections
April 2015 Volume 59 Number 4 aac.asm.org 2119Antimicrobial Agents and Chemotherapy
prediction of in vivo activity is very challenging, due to variations
in potency that can occur due to many uncontrolled parameters in
the host systems (58, 59). Despite the challenges of using in vitro
potency to predict in vivo potency, we found that the most potent
peptide in the in vitro study, pYR, was also the most potent peptide
in treating S. aureus skin infections in mice. pYR (at 3 mg · kg	1)
reduced bacterial loads in the wounds similarly to the positive-
control compound neomycin sulfate (at 10 mg · kg	1), a broad-
spectrum antibiotic that is used in topical ointments and is most
effective against S. aureus (48).
In conclusion, this study has investigated a class of -sheet
multifunctional antimicrobial peptides that are effective in treat-
ing S. aureus skin infections in a murine model. Although cycliza-
tion was shown previously to enhance stability and bioactivity (28,
60), in this case an improvement in stability was observed but
bioactivity was reduced. Structural or charge distribution changes
upon cyclization might be responsible for the decreased antimi-
crobial activity. The choice of peptide for further development
(open versus cyclic) reflects a balance between stability and
bioactivity. Further studies are needed to investigate the mech-
anisms of action of these peptides, to fully explore their poten-
tial for clinical use.
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